Section Arrow
Quote
SNTI.NASDAQ
- Senti Biosciences Holdings Inc.
Quotes are at least 15-min delayed:2026/06/01 23:21 EDT
Regular Hours
Last
 0.9803
+0.0287 (+3.02%)
Day High 
1.02 
Prev. Close
0.9516 
1-M High
1.0901 
Volume 
278.22K 
Bid
0.976
Ask
0.9869
Day Low
0.94 
Open
0.9426 
1-M Low
0.8603 
Market Cap 
29.64M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 0.97 
20-SMA 0.98 
50-SMA 0.95 
52-W High 3.8844 
52-W Low 0.770167 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.46/-0.94
Enterprise Value
53.20M
Balance Sheet
Book Value Per Share
0.08
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
22.00K
Operating Revenue Per Share
0.10
Industry Comparison
More
Code Name   Last Change Change (%) P/E P/E Range
AIMAIM ImmunoTech Inc.0.8986+0.4908+120.35%-- 
GNTAGenenta Science SpA1.65+0.62+60.19%-- 
OTLKOutlook Therapeutics0.843+0.113+15.48%-- 
ADTXAditxt Inc.0.113-0.0042-3.58%-- 
RXRXRecursion Pharmaceuticals3.79+0.2+5.57%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.